John Pritchard discusses the history of the nebuliser, its fall in popularity with the advent of DPIs and pMDIs, and its current resurgence due to the success of the mesh nebuliser, continuing on to how changing the development paradigm to utilise nebuliser technology more effectively can have significant benefits.
Anselm Ebert, João Ventura Fernandes, Ameet Sule and Sunita Sule discuss the rising need for respiratory medication in the developing world. They go on to highlight the novel challenges presented by these new markets and explain how a new DPI, PowdAir Plus™, meets those challenges, offering a solution to the increase in chronic respiratory conditions across the globe.
Brian Jones and Susana Ecenarro Probst discuss the growing interest in using inhaled APIs to treat systemic conditions. Furthermore, they review some of the methods used to engineer molecules to be suitable for DPI capsules and look to the possibility of administering biomolecules via the pulmonary route.
Pulmonary drug delivery is an effective route of pharmaceutical administration but research has shown that a large majority of patients fail to use their devices properly, training devices can help address this problem. Joe Reynolds looks at the design challenges that need to be addressed as well as some of the latest features that can be incorporated to develop optimal training devices for patients.